RxDoctor Payments Data

Tracy Lillie

Family Medicine · Huntingdon, PANPI 1689650848

Payments from drug & device makers

$4,596in general payments, 2019–2025

Across 296 payments — averaging $15.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$784
  • Novo Nordisk$640
  • GSK$531
  • AbbVie$375
  • Astellas Pharma US Inc$253
  • AstraZeneca$230
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,47297%
  • Education$1243%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,596 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide77$82,175
MounjaroTirzepatide32$46,686
EliquisApixaban49$42,745
XareltoRivaroxaban29$40,624
JardianceEmpagliflozin35$39,724
FarxigaDapagliflozin Propanediol28$25,370
JanuviaSitagliptin Phosphate26$24,695
Soliqua 100-33Insulin Glargine/Lixisenatide14$20,944
Breo ElliptaFluticasone/Vilanterol32$18,436
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog33$14,899
MyrbetriqMirabegron22$14,124
EntrestoSacubitril/Valsartan27$13,904
OzempicSemaglutide12$11,140
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,062
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$9,001

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$784$128,861109 claims
PfizerEliquis$156$42,74549 claims
Johnson & JohnsonXarelto$155$40,62429 claims
Boehringer IngelheimJardiance$178$39,72435 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$531$38,49968 claims
AstraZenecaFarxiga$230$25,37028 claims
MerckJanuvia$54$24,69526 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$118$20,94414 claims
Astellas Pharma US IncMyrbetriq$253$14,12422 claims
NovartisEntresto$227$13,90427 claims
Novo NordiskOzempic$640$11,14012 claims
AbbVieSynthroid$375$1,95852 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Huntingdon

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →